Inozyme Pharma Inc

Inozyme Pharma — Technical Presentation (May 2024)

19 slides from Inozyme Pharma's technical presentation, May 26, 2024

  1. Slide 1: Impact of INZ-701 on Bone and Mineral Metabolism Biomarkers and Clinical Outcomes in Adults with ENPP1 Deficiency

    Impact of INZ-701 on Bone and Mineral Metabolism Biomarkers and Clinical Outcomes in Adults with ENPP1 Deficiency – Results from 48-week Phase 1/2 Open Label Study Yves Sabbagh,1 Robert Wermers,2 Rainard Fuhr,3 Dirk Schnabel,4 Alix Bensacon,5 Deborah Wenkert6, Kurt Gunter1 1Inozyme Pharma, Boston, U

  2. Slide 2: Disclosures

    Disclosures This study was funded by Inozyme Pharma. • YS and KG are employees of and stockholders in Inozyme Pharma. • DW is a former employee of Inozyme Pharma. • RF is an employee of Parexel, the sponsor’s CRO for study conduct. • RW, DS and AB have nothing to disclose.

  3. Slide 3: ENPP1 is a key component of the pyrophosphate-adenosine pathway

    ENPP1 is a key component of the pyrophosphate-adenosine pathway1-3 1 ABCC6 and ANK 2 3 Pyrophosphate (PPi) regulates CD73 metabolizes transport ATP from ENPP1 metabolizes AMP into Pi and skeletal mineralization1 intracellular to ATP into PPi and AMP adenosine extracellular space Adenosine inhibits v

  4. Slide 4: Low PPi and low adenosine due to ENPP1 Deficiency lead to ectopic calcification and arterial intimal proliferation

    Low PPi and low adenosine due to ENPP1 Deficiency lead to ectopic calcification and arterial intimal proliferation1-3 Low PPi levels lead to soft tissue mineralization1 Low adenosine levels lead to intimal proliferation and artery lumen narrowing1-3 Nonfunctional ENPP1 enzyme ENPP1 gene mutation(s)

  5. Slide 5: The Natural History of ENPP1 Deficiency

    The Natural History of ENPP1 Deficiency1-5 INFANCY* CHILDHOOD/ ADOLESCENCE ADULTHOOD Rickets (Xray) Osteomalacia (Xray) Findings Arterial calcification (CT, US) Hypophosphatemia, inc. FGF23 (labs) Hypophosphatemia, inc FGF23 (labs) Arterial stenosis (CTA, US) Joint/ ligament calcification (X-ray, CT

  6. Slide 6: Adult ENPP1 Deficiency Phase 1/2 trial

    Adult ENPP1 Deficiency Phase 1/2 trial A Phase 1/2, open-label, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 followed by an open-label long-term extension period in adults with ENPP1 Deficiency Study Population: Primary Goals S

  7. Slide 7: Purpose

    Purpose: To describe the safety and exploratory efficacy of INZ-701 in adults with ENPP1 Deficiency through the end of the phase 2 study period (week 48). 7

  8. Slide 8: Results: Baseline Demographics

    Results: Baseline Demographics Cohort 1 Cohort 2 Cohort 3 Cohort 4 0.2 mg/kg 0.6 mg/kg 1.8 mg/kg 1.2 mg/kg biweekly biweekly biweekly weekly (n=3) (n=3) (n=3) (n=4) AGE (YEARS) Median 31 43 25 29 Range 23-40 30-58 22-29 20-58 GENDER Male (n=5) 0 1 2 2 Female (n=8) 3 2 1 2 RACE White (n=9) 3 3 2 1 As

  9. Slide 9: Results: Medical History

    Results: Medical History Cohort 1 Cohort 2 Cohort 3 Cohort 4 0.2 mg/kg 0.6 mg/kg 1.8 mg/kg 1.2 mg/kg Total MEDICAL CONDITION biweekly biweekly biweekly weekly (n=13) (n=3) (n=3) (n=3) (n=4) Rickets/osteomalacia 3 2 3 4 12 Cardiovascular disease 2 3 2 3 10 Arterial calcification/stenosis/surgery 2 3

  10. Slide 10: INZ-701 exhibited a favorable safety profile across dosing cohorts

    INZ-701 exhibited a favorable safety profile across dosing cohorts INZ-701 dose cohort – No. of patients with at least one event 0.2 mg/kg 0.6 mg/kg 1.8 mg/kg 1.2 mg/kg Total patients Event biweekly biweekly biweekly weekly (n=13) n=3 n=3 n=3 n=4 Adverse event (AE) 3 3 2 3 11 Adverse event related t

  11. Slide 11: Favorable immunogenicity profile observed

    Favorable immunogenicity profile observed Low, non-neutralizing anti-drug antibodies (ADAs) were detected; Transient in at least 3 of 11 patients Anti-Drug Antibody (ADA) Status and Titers Weeks 2 3 4 5 12 24 36 48 60 72 84 96 Highest ADA titer Cohort 1 1 40 40 80 40 160 40 <40 160 2 80 40 80 3 80 W

  12. Slide 12: Plasma PPi by Dosing Group

    Results: Plasma PPi by Dosing Group Phase 1 Phase 2 3000 (0.2mg/kg) 2500 Cohort 1 Plasma PPi (nM) 2000 1500 1000 • Rapid increase observed after the 500 1st dose 0 0 10 20 30 40 100 200 300 400 500 600 700 3000 Days • PPi levels reached the healthy (0.6mg/kg) volunteer range after the 1st dose Plasm

  13. Slide 13: Pooled Plasma PPi, Serum FGF-23, and Serum Pi

    Results: Pooled Plasma PPi, Serum FGF-23, and Serum Pi Pooled Cohorts 1-3: Baseline vs mean Week 2-48 PPi, FGF-23, and Pi levels (±SEM) 3000 Plasma PPi 150 2.6 Serum Pi Serum FGF-23 Serum Pi (mg/dL) FGF-23 (pg/mL) 2.4 Plasma PPi (nM) 2000 100 2.2 Baseline 50 2.0 1000 1.8 0 1.6 0 0 10 20 30 40 50 0 1

  14. Slide 14: Bone Mineral Biomarkers by Dosing Group

    Results: Bone Mineral Biomarkers by Dosing Group Cohort 1 Cohort 2 Cohort 3 (0.2mg/kg, 2x/week) (0.6mg/kg, 2x/week) (1.8mg/kg, 2x/week) 75 75 75 (% change from baseline) (% change from baseline) (% change from baseline) Bone-specific alkaline phosphatase (BSAP): Key 50 50 50 enzyme involved in miner

  15. Slide 15: 6-Minute Walk Test (6-MWT) by Dosing Group and by Baseline 6-MWT

    Results: 6-Minute Walk Test (6-MWT) by Dosing Group and by Baseline 6-MWT Greater improvement observed in patients with poor baseline 6-MWT 4 Cohort 1 Patients with <70% predicted of healthy 6-MWT at baseline (n=5) 6-MWT 6-MWT % Predicted Normal Serum Pi (mg/dL) Cohort 2 100 550 6-MWT Absolute Dista

  16. Slide 16: PROMIS Scale (PRO) by Dosing Group

    Results: PROMIS Scale (PRO) by Dosing Group Improvements seen at all dose levels Pain Intensity Pain Interference Fatigue Responders Responders Responders Cohort Cohort Cohort (n) (n) (n) Cohort 1 Cohort 1 Cohort 1 Cohort 2 Cohort 2 Cohort 2 Cohort 3 Cohort 3 Cohort 3 Total Total Total Responder def

  17. Slide 17: Global Impression of Change Scale

    Results: Global Impression of Change Scale Cohort 1 (0.2mg/kg) (n=3) Cohort 2 (0.6mg/kg) (n=3) Cohort 3 (1.8mg/kg) (n=3)* 3 3 3 Global Clinician’s Global 2 2 2 Impression Impression 1 1 1 Clinician’s C-GIC C-GIC C-GIC 0 0 0 10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 -1 -1 -1 Weeks Weeks Weeks -2 -

  18. Slide 18: Conclusions

    Conclusions Phase 1/2 trial of INZ-701 in adults with ENPP1 Deficiency successfully met all study objectives • Study fully enrolled in all 4 cohorts (n=13) • PK data from cohort 4 support once per week dosing in future clinical studies in ENPP1 Deficiency • Favorable safety profile was maintained o

  19. Slide 19: Acknowledgements

    Acknowledgements The authors would like to thank the patients and their families who took part in this clinical study. We acknowledge the contributions of investigators and study coordinators. 19

Inozyme Pharma — Technical Presentation (May 2024) on 6ix